1. Home
  2. GSM vs AKBA Comparison

GSM vs AKBA Comparison

Compare GSM & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferroglobe PLC

GSM

Ferroglobe PLC

HOLD

Current Price

$4.88

Market Cap

856.6M

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.53

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSM
AKBA
Founded
2015
2007
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
856.6M
729.1M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GSM
AKBA
Price
$4.88
$1.53
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$6.00
$6.25
AVG Volume (30 Days)
840.9K
2.8M
Earning Date
02-18-2026
11-10-2025
Dividend Yield
1.14%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,373,244,000.00
$225,071,000.00
Revenue This Year
N/A
$52.38
Revenue Next Year
$22.56
$22.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.49
52 Week Low
$2.97
$1.45
52 Week High
$5.74
$4.08

Technical Indicators

Market Signals
Indicator
GSM
AKBA
Relative Strength Index (RSI) 61.42 39.71
Support Level $4.67 $1.46
Resistance Level $4.95 $1.57
Average True Range (ATR) 0.17 0.06
MACD 0.02 0.00
Stochastic Oscillator 81.52 20.37

Price Performance

Historical Comparison
GSM
AKBA

About GSM Ferroglobe PLC

Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's business segments include North America- Silicon, North America -Silicon Alloys; Europe Manganese; Europe Silicon Metals; Europe -Silicon Alloys, South Africa Silicon Metals, South Africa-Silicon Alloys, and Other segments The primary raw materials company uses to produce its electrometallurgy products includes its coal and quartz mining operations and its silicon metal and ferroalloy production.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: